Apollo drops 2.3% as India drug-price risk puts UAE hospital pharmacy margins on watch

Apollo Hospitals Enterprise fell 2.3% and Max Healthcare Institute dropped 2.2% in early trade on 1 October 2026, after Indian investors priced in the risk of tighter controls on medicine mark-ups at private hospitals, Moneycontrol reported.

The highest-stakes readers in the UAE are CFOs, COOs and pharmacy heads. The immediate lesson is margin exposure. In Dubai, the Dubai Health Authority (DHA) regulates private health facilities, while medicine pricing sits with federal drug authorities and Ministry of Health and Prevention (MOHAP) decisions. In Abu Dhabi and Al Ain, the Department of Health Abu Dhabi (DOH) controls facility and insurance rules. In the northern emirates, MOHAP remains the main health regulator for facilities.

What moved Indian hospital shares

The sell-off followed observations by India’s Supreme Court on hospital medicine mark-ups. Moneycontrol reported that the court questioned whether a uniform 16% margin could apply to medicines, and cited a cancer drug with a retailer price of Rs 2,700 and a maximum retail price of Rs 27,000. No binding price-control order had been issued at the time of the report.

The market reaction was larger than the legal event. Apollo ended the previous session down 6.6%, Fortis Healthcare lost 6.9%, Max fell 5.8% and Aster DM Quality Care declined 5.2%. Jefferies estimated that medicines and consumables account for about 15-20% of hospital revenue, with a possible 2-5% EBITDA hit under price-cap scenarios if hospitals cannot pass on the impact, according to Moneycontrol.

For UAE operators, the Indian move is a warning on valuation, billing design and payer relations. Pharmacy income may look stable until a court, regulator or insurer asks whether the spread between acquisition cost, approved price and patient charge is defensible.

Why Dubai operators should care first

DHA has already used circulars to push MOHAP medicine-pricing decisions into Dubai’s private sector. On 11 March 2022, DHA issued circular CIR-2022-00000058 on ministerial decrees 12, 13 and 14 of 2022 regarding medication selling prices, telling all Dubai private health facilities and practitioners to adhere to MOHAP decisions.

That gives Dubai clinics and hospital pharmacies a clear control point. The pharmacy file should reconcile three items before a payer or patient dispute arrives:

• The product’s federal registration and approved public price, using the Emirates Drug Establishment registered medical product directory.
• The facility’s acquisition cost and any group procurement rebates, recorded by batch and supplier.
• The insurer contract rule for pharmacy dispensing, co-pay, exclusions and medicine sub-limits.
• The patient invoice line, including VAT treatment where applicable and any excluded item charged in cash.

The check matters for Daman, Thiqa and Sukoon members only where the patient’s policy, network and emirate make those schemes relevant. Operators should verify the applicable formulary and network file inside the payer portal rather than using a public brochure as the billing source.

What Abu Dhabi and MOHAP facilities should audit

Abu Dhabi has a different control surface. DOH lists a tool for consumers to search approved drugs available in the Abu Dhabi market, and another tool to search health insurance products by annual coverage, medicine sub-limit and other benefits. DOH’s lists and tools page was last updated on 30 September 2026.

For manufacturers and warehouses, the federal process is explicit. The Emirates Drug Establishment says repricing a single registered medical product takes 90 working days. The listed fees are AED 1,000 for repricing and AED 500 for a new pricing certificate. Required documents include a country-of-origin price certificate, reasons for repricing and reference prices from Gulf and European countries.

COOs in Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah should treat the Indian episode as a reason to test pharmacy governance before the next payer audit. The audit should include MOHAP price files, EDE registration status, supplier invoices, controlled-medicine records and insurer-specific billing edits.

The patient implication is narrower but material. If pharmacy mark-ups face more scrutiny across the region, patients may see tighter substitution rules, more prior authorisation for high-cost oncology and specialty drugs, and closer checks on whether a medicine must be bought through an in-house pharmacy. The practical step is simple: verify the provider licence before prescribing, dispensing or reimbursing. Use the UAE Open Healthcare Directory to identify licensed pharmacy providers, then cross-check Dubai providers with DHA, Abu Dhabi providers with DOH and northern emirates providers with MOHAP.